Clinical Trial Update: Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing Capmatinib to Docetaxel in previously treated non-small cell lung cancer with MET exon 14 skipping mutation was terminated, with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Capmatinib (capmatinib)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: TERMINATED | Results posted: 2025-01-30